Sleep Medication Market Report 2026

The sleep medication market size has grown strongly in recent years. It will grow from $25.92 billion in 2025 to $28.06 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to limited availability of advanced sleep medications, growing insomnia cases, reliance on prescription-based sleep drugs, increasing hospital-based sleep disorder treatments, emergence of benzodiazepines as primary therapy.

The sleep medication market size is expected to see strong growth in the next few years. It will grow to $38.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of orexin receptor antagonists, rising use of melatonin receptor agonists, growth in otc sleep supplements, expansion of homecare and speciality sleep centres, increasing telemedicine and online pharmacy adoption. Major trends in the forecast period include rising prevalence of sleep disorders globally, increased adoption of non-benzodiazepine hypnotics, growth in herbal and dietary sleep supplements, expansion of online pharmacy distribution channels, rising awareness about sleep health and wellness.

The rising prevalence of mental illness is anticipated to drive the growth of the sleep medication market in the coming years. Mental illness encompasses a broad range of mental health conditions that influence an individual’s mood, thought processes, behavior, and overall daily functioning. The increasing occurrence of mental illness is largely linked to escalating levels of chronic stress, as prolonged stress can disrupt normal brain function and either trigger or exacerbate mental health disorders. Sleep medications support individuals with mental illness by improving sleep quality, which is frequently impaired in many mental health conditions. These medications help regulate the sleep-wake cycle, alleviate symptoms such as insomnia and anxiety, and thereby enhance overall mental well-being and daily performance. For example, in 2025, according to the National Alliance on Mental Illness and NextStep Solutions Behavioral Health, US-based health agencies reported that the prevalence of serious mental illness (SMI) was approximately 5.44% in 2023 and remained similar in 2024 at around 5.6% of adults, indicating relative stability within this severe category. Therefore, the increasing prevalence of mental illness is contributing to the growth of the sleep medication market.

Major companies operating in the sleep medication market are concentrating on the development of innovative products, including treatments for moderate-to-severe obstructive sleep apnea, to broaden their therapeutic portfolios and address the growing demand for advanced sleep disorder solutions. Moderate-to-severe obstructive sleep apnea is a serious sleep condition characterized by repeated airway obstructions during sleep, leading to frequent interruptions in breathing, significantly reduced oxygen levels, and disrupted sleep quality. For instance, in December 2024, Eli Lilly and Company, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration approved Zepbound (tirzepatide) as the first prescription therapy specifically indicated for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Intended for use alongside calorie reduction and increased physical activity, Zepbound introduces a new pharmacological option for improving OSA outcomes. This approval underscores the growing clinical need for effective OSA treatments, a condition that is often underestimated despite its substantial impact on sleep quality, daytime functioning, and overall health.

In July 2024, Cosette Pharmaceuticals Inc., a US-based pharmaceutical company, acquired Ambien (zolpidem tartrate), a fast-acting sleep medication, and Ambien CR tablets (6.25 mg once daily immediately before bedtime) from Sanofi S.A. for an undisclosed amount. Through this acquisition, Cosette Pharmaceuticals significantly strengthened its presence in the U.S. sleep medicine market by adding well-established insomnia treatments to its product portfolio. Sanofi S.A. is a France-based pharmaceutical company engaged in the development of sleep medications.

Major companies operating in the sleep medication market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Perrigo Company plc, H. Lundbeck A/S, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Vanda Pharmaceuticals Inc., Natrol LLC.

North America was the largest region in the sleep medication market in 2025. The regions covered in the sleep medication market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sleep medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the sleep medication market by increasing costs for imported active pharmaceutical ingredients (APIs) and formulation chemicals, impacting prescription-based drugs and OTC supplements. Segments such as benzodiazepines and melatonin receptor agonists are particularly affected, with Asia-Pacific regions like China and India experiencing higher import duties. This has led to increased production costs and pricing adjustments. On the positive side, tariffs are encouraging local manufacturing of sleep medications, promoting domestic pharmaceutical innovation, and improving supply chain resilience.

The sleep medication market research report is one of a series of new reports that provides sleep medication market statistics, including sleep medication industry global market size, regional shares, competitors with a sleep medication market share, detailed sleep medication market segments, market trends and opportunities, and any further data you may need to thrive in the sleep medication industry. This sleep medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sleep medication refers to pharmaceutical agents developed to help individuals fall asleep more quickly, maintain sleep for longer periods, or enhance overall sleep quality. The main objective of sleep medication is to manage sleep disorders, such as insomnia, by regulating the body’s sleep-wake cycle.

The main types of sleep medication include prescription-based drugs and over-the-counter (OTC) drugs. Prescription-based drugs are medications that require a physician’s prescription due to their strength, potential side effects, or the need for clinical supervision. Sleep medications are used to treat various sleep disorders, including insomnia, sleep apnea, restless legs syndrome, narcolepsy, sleepwalking, and others. They are classified into categories such as benzodiazepines, antidepressants, antihistamines, sedating antipsychotics, and other drug classes. These medications are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are used by key end users such as hospitals, homecare settings, specialty centers, and others.

The sleep medication market consists of sales of hormonal sleep aids, anticonvulsants, cannabinoids, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.